We invited speakers at the forefront of AI for drug discovery in academia and industry.
Geometric Deep Learning: From Euclid to Drug Design
DeepMind Professor of AI @ Oxford
Head of Graph ML @ Twitter
Scientific Advisor @ Relation Therapeutics
Professor Bronstein is the DeepMind Professor for AI at the University
of Oxford and Head of
Graph Machine Learning Research at Twitter. He is widely regarded as the ‘father’ of
Geometric Deep Learning (a term he coined) and has published a highly regarded textbook of
the same name.
A serial entrepreneur, one of Michael’s companies, Fabula AI, was the first known commercial success of Graph Neural Networks when it was acquired by Twitter in 2019. Previously, he has held academic positions at Harvard, MIT, Stanford, Imperial, Radcliffe Institute, TUM, Tel Aviv and Technion and he also is a Scientific Advisor at Relation Therapeutics.
Prof Emeritus of Biochemistry @ Cambridge
Co-Founder @ Astex Therapeutics
Former President of the UK Science Council
Sir Tom is a highly interdisciplinary biochemist, structural biologist, computational biologist and science administrator. He is well known for his work on experimental structural biology of hormones, growth factors and DNA-repair, for his computational work on protein modelling (Modeller that has 13,000 citations), for computer-aided drug design (CADD) and for pioneering the technique of Fragment-based Drug Design (FBDD). He was a member of the team of Dorothy Hodgkin that solved in 1969 the first structure of a protein hormone, insulin. In 1999, he co-founded the oncology company Astex Therapeutics, which has moved ten drugs into clinical trials. Previously, he has served as an elected Labour member of Oxford City Council and has been a Scientific Advisor to the Tory Prime Minister Margaret Thatcher at No. 10 Downing Street, after which he famously restructured British science research councils, founding BBSRC in 1992.
AI in Drug Discovery 2022 – Aspects of Translation, Platform Validation, and Where We are on the Hype Cycle
CTO @ Terra Lumina
Professor of Molecular Informatics @ Cambridge
Andreas leads a research group in the Centre for Molecular Informatics at University of Cambridge, focusing on data-driven chemical and biological screenings for detecting mechanisms of action and adverse drug reactions, especially related to cancer. He is also the co-founder and Chief Technology Officer Terra Lumina, a new company working on harnessing the power of AI to unlock the therapeutic potential of nature's small molecules. He has previously held industry positions with Novartis and AstraZeneca and he is also the co-founder of the Healx and PharmEnable startups which specialise in AI-driven small molecule discovery for various disease areas, including neurodegenerative, inflammation and rare diseases.
Scientific tool of the 21st century: Introduction to Graph Neural Networks
Staff Research Scientist @ DeepMind
Affiliated Lecturer @ University of Cambridge
Petar is a Staff Research Scientist at Google DeepMind and an Affiliated Lecturer at the University of Cambridge. He is the first author of ‘Graph Attention Networks’ which proposed a now ubiquitous convolution layer for GNNs and is a co-author of the textbook ‘Geometric Deep Learning’. His research has been used to substantially improve travel time estimates for Google Maps and to solve-top-tier theorems and conjectures in mathematics. In addition to being a prolific researcher in the field of GNNs, he is also a pioneer in the new field of ‘Neural Algorithmic Reasoning’ and passionate science communicator.
Talk title tbc
CEO/Founder @ Ladder TherapeuticsToggle bio
Rabia is Founder and CEO of Ladder Therapeutics, a startup using AI to design therapeutics for a novel class of targets, non-targeting RNAs. She holds a PhD in Genetics from McGill University, is an associate at the Creative Destruction Lab and a passionate advocate for getting more women involved in tech and STEM. Previously, she has held Directorships at Sensyne Health and BenevolentAI as well being a Postdoctoral Fellow at the Francis Crick Institute.
Using Cause-and-Effect to Empower Drug Discovery
CEO/Founder @ BiorelateToggle bio
Daniel founded Biorelate during his PhD in computational biology at the University of Manchester. After having supported the successful identification of drug repurposing opportunities with Pfizer, Daniel is now focusing on growing Biorelate into a world leading enterprise, helping pioneering companies in their mission to develop life-saving innova- tions. He co-developed Galactic AITM, a supercomput-ing platform that automatically curates biomedical research to dramatically improve the understanding of a particular research area in drug discovery. By connecting obfuscated evidence, Biorelate’s goal is to accelerate development of important new therapies.
Talk title tbc
CEO/Founder @ OneTree BiotechToggle bio
Neel received his PhD from the Weill Medical College of Cornell University, using data analytics and machine learning to study cancer systems biology and to help improve precision patient care. He authored numerous scientific publications in the fields of machine learning, pharmacology, and precision medicine. To date, his work has led to the development of new AI prediction methods, the discovery of a novel class of cancer therapeutics, and the start of new clinical trials. During his postdoctoral studies at Cornell, he established OneThree Biotech, which develops machine learning technologies for providing insights across multiple parts of the drug development pipeline.
CEO/Founder @ Charm TherapeuticsToggle bio
Laksh holds a Double First Class degree in Natural Sciences from the University of Cambridge with a focus on drug discovery. Previously, he spent 2 years as a Machine Learning Engineer at Exscientia in Oxford, a world leading AI in drug discovery company which currently has a current market capitalisation of over $2 billion after a successful IPO in 2021. In October 2021, he founded CHARM Therapeutics, a new startup leveraging recent breakthroughs in “3-D deep learning on molecular configurations”. He is also the Founder of genei, a Y-Combinator backed AI web tool to help researchers to research faster.
Founder and General Partner @ Air Street Capital
Founder @ RAAIS, London.AI and Spinout.fyi
Co-author of State of AI report
Nathan is the General Partner of Air Street Capital, a venture capital firm investing in AI-first technology and life science companies, including LabGenius, Exscientia and Valence Discovery. He founded RAAIS and London.AI (AI community for industry and research), the RAAIS Foundation (funding open-source AI projects), and Spinout.fyi (improving university spinout creation). He is also the co-author of the annual “State of AI” report, which provides an excellent qualitative and quantitative deep dive into AI at the intersection of research, talent, industry and politics. He studied biology at Williams College and earned a PhD from the University of Cambridge in computational biology and cancer research.
All talks will include 5-10 minutes for Q&A at the end.
Times are given in the GMT timezone.
[Zoom link - Session 1]
Talk | Petar Veličković
Scientific tool of the 21st century: Introduction to Graph Neural Networks[Zoom link - Session 1]
Talk | Andreas Bender
AI in Drug Discovery 2022 – Aspects of Translation, Platform Validation, and Where We are on the Hype Cycle[Zoom link - Session 1]
|11:30||Break | 20 min|
Talk | Michael Bronstein
Geometric Deep Learning: From Euclid to Drug Design[Zoom link - Session 2]
Talk | Rabia Khan
Title TBA[Zoom link - Session 2]
|13:10||Break | 50 min|
Talk | Neel Madhukar
Title TBA[Zoom link - Session 3]
Talk | Daniel Jamieson
Using Cause-and-Effect to Empower Drug Discovery[Zoom link - Session 3]
|15:20||Break | 10 min|
Panel | How to start an AI in Drug Discovery company
Rabia Khan, Daniel Jamieson, Neel Madhukar, Laksh Aithani[Zoom link - Session 4]
Panel | Scientific frontiers in AI and Drug Discovery
Tom Blundell, Michael Bronstein, Nathan Benaich[Zoom link - Session 5]
AI for medicine
AI for environmental risk
AI for environmental risk